The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study

INTRODUCTION: Imeglimin is a novel antidiabetic drug that amplifies glucose-stimulated insulin secretion (GSIS) and improves insulin sensitivity. Several randomized clinical studies have shown the efficacy of imeglimin for glycemic control in patients with type 2 diabetes (T2D). We aimed to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Oda, Tomoyasu, Satoh, Marino, Nagasawa, Kan, Sasaki, Atsumi, Hasegawa, Yutaka, Takebe, Noriko, Ishigaki, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399333/
https://www.ncbi.nlm.nih.gov/pubmed/35895275
http://dx.doi.org/10.1007/s13300-022-01298-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399333/
https://www.ncbi.nlm.nih.gov/pubmed/35895275
http://dx.doi.org/10.1007/s13300-022-01298-w

Ejemplares similares